Sarah B. Goldberg, Mary Weber Redman, David Ross Camidge, Katherine Minichiello, Louise Highleyman, Jyoti D. Patel, Tom Stinchcombe, Jeffrey D. Bradley, Julie R. Brahmer, Hossein Borghaei, Jhanelle E. Gray, Saiama Naheed Waqar, Karen L. Reckamp, Roy S. Herbst, Karen Kelly, Helen J. Ross. "A randomized phase II study of capmatinib plus osimertinib with or without ramucirumab in patients with
                    <i>EGFR</i>
                    -mutant,
                    <i>MET</i>
                    -amplified stage IV or recurrent no–small cell lung cancer (Lung-MAP Sub-Study S1900G).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps8677